Prevention of venous thromboembolism in acute medical illness

Jason M. Enders, John M. Burke, Paul P. Dobesh

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Each year millions of patients experience a venous thromboembolic event. Due to the significant morbidity and mortality associated with venous thromboembolism (VTE), prevention is critical. Several groups, such as those undergoing orthopedic or general surgery, and patients experiencing acute myocardial infarction, are known to be at high risk for VTE. General medical patients - the medically ill - are also at risk, but they receive insufficient prophylaxis, which may be due to underestimation or lack of assessment of their risk. The American College of Chest Physicians recommends either unfractionated heparin or low-molecular-weight heparin to prevent VTE in these patients. The different pharmacologic profiles and dosing methods of these two groups of agents suggest that efficacy and safety may not be equivalent. Due to heterogeneity of medically ill patients and variability in clinical trials, a detailed review of the literature was performed to assist clinicians in assessing risk and choice of a regimen to prevent VTE.

Original languageEnglish (US)
Pages (from-to)1564-1578
Number of pages15
JournalPharmacotherapy
Volume22
Issue number12 I
DOIs
StatePublished - Dec 1 2002

Fingerprint

Venous Thromboembolism
Low Molecular Weight Heparin
Orthopedics
Heparin
Myocardial Infarction
Clinical Trials
Morbidity
Safety
Mortality

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Prevention of venous thromboembolism in acute medical illness. / Enders, Jason M.; Burke, John M.; Dobesh, Paul P.

In: Pharmacotherapy, Vol. 22, No. 12 I, 01.12.2002, p. 1564-1578.

Research output: Contribution to journalReview article

Enders, Jason M. ; Burke, John M. ; Dobesh, Paul P. / Prevention of venous thromboembolism in acute medical illness. In: Pharmacotherapy. 2002 ; Vol. 22, No. 12 I. pp. 1564-1578.
@article{a2cc9ef0b2d7477a81807be47ad2cfa6,
title = "Prevention of venous thromboembolism in acute medical illness",
abstract = "Each year millions of patients experience a venous thromboembolic event. Due to the significant morbidity and mortality associated with venous thromboembolism (VTE), prevention is critical. Several groups, such as those undergoing orthopedic or general surgery, and patients experiencing acute myocardial infarction, are known to be at high risk for VTE. General medical patients - the medically ill - are also at risk, but they receive insufficient prophylaxis, which may be due to underestimation or lack of assessment of their risk. The American College of Chest Physicians recommends either unfractionated heparin or low-molecular-weight heparin to prevent VTE in these patients. The different pharmacologic profiles and dosing methods of these two groups of agents suggest that efficacy and safety may not be equivalent. Due to heterogeneity of medically ill patients and variability in clinical trials, a detailed review of the literature was performed to assist clinicians in assessing risk and choice of a regimen to prevent VTE.",
author = "Enders, {Jason M.} and Burke, {John M.} and Dobesh, {Paul P.}",
year = "2002",
month = "12",
day = "1",
doi = "10.1592/phco.22.17.1564.34124",
language = "English (US)",
volume = "22",
pages = "1564--1578",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "12 I",

}

TY - JOUR

T1 - Prevention of venous thromboembolism in acute medical illness

AU - Enders, Jason M.

AU - Burke, John M.

AU - Dobesh, Paul P.

PY - 2002/12/1

Y1 - 2002/12/1

N2 - Each year millions of patients experience a venous thromboembolic event. Due to the significant morbidity and mortality associated with venous thromboembolism (VTE), prevention is critical. Several groups, such as those undergoing orthopedic or general surgery, and patients experiencing acute myocardial infarction, are known to be at high risk for VTE. General medical patients - the medically ill - are also at risk, but they receive insufficient prophylaxis, which may be due to underestimation or lack of assessment of their risk. The American College of Chest Physicians recommends either unfractionated heparin or low-molecular-weight heparin to prevent VTE in these patients. The different pharmacologic profiles and dosing methods of these two groups of agents suggest that efficacy and safety may not be equivalent. Due to heterogeneity of medically ill patients and variability in clinical trials, a detailed review of the literature was performed to assist clinicians in assessing risk and choice of a regimen to prevent VTE.

AB - Each year millions of patients experience a venous thromboembolic event. Due to the significant morbidity and mortality associated with venous thromboembolism (VTE), prevention is critical. Several groups, such as those undergoing orthopedic or general surgery, and patients experiencing acute myocardial infarction, are known to be at high risk for VTE. General medical patients - the medically ill - are also at risk, but they receive insufficient prophylaxis, which may be due to underestimation or lack of assessment of their risk. The American College of Chest Physicians recommends either unfractionated heparin or low-molecular-weight heparin to prevent VTE in these patients. The different pharmacologic profiles and dosing methods of these two groups of agents suggest that efficacy and safety may not be equivalent. Due to heterogeneity of medically ill patients and variability in clinical trials, a detailed review of the literature was performed to assist clinicians in assessing risk and choice of a regimen to prevent VTE.

UR - http://www.scopus.com/inward/record.url?scp=0036894230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036894230&partnerID=8YFLogxK

U2 - 10.1592/phco.22.17.1564.34124

DO - 10.1592/phco.22.17.1564.34124

M3 - Review article

C2 - 12495167

AN - SCOPUS:0036894230

VL - 22

SP - 1564

EP - 1578

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 12 I

ER -